Northwire Canada EditionThursday, July 16, 2026
Northwire
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Financings

LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING

LSL · Price

Executive Summary

  • LSL Pharma Group completed the acquisition of Juno OTC Inc. for a total purchase price of $5 million, consisting of cash, shares, and a deferred cash balance.
  • Concurrently, the company closed an upsized $12 million private placement, including a $2 million tranche of non-brokered convertible debentures, bringing total gross proceeds to $12 million.
  • The acquisition involves an arm's length transaction subject to TSXV approval, with operational control of Juno OTC remaining with the Seller until January 1, 2026.

Key Details

  • Acquisition Structure:
    • Target: Juno OTC Inc. (Toronto-based subsidiary of Juno Pharmaceuticals LP).
    • Total Purchase Price: $5,000,000.
    • Payment Terms:
      • $2,500,000 in cash paid on December 23, 2025.
      • 5,509,642 Class "A" common shares issued on the closing date.
      • $500,000 in cash payable on January 1, 2027 (subject to working capital adjustments).
    • Operational Control: Seller retains operational control and financial liability through December 31, 2025; Corporation assumes full control effective January 1, 2026.
    • Regulatory Status: Qualifies as an "Expedited Acquisition" under TSXV Policy 5.3; subject to final TSXV approval. Securities issued are subject to a 4-month and 1-day statutory hold period.
  • Financing Details (Non-Brokered Private Placement):
    • Instrument: Unsecured convertible debentures.
    • Quantity: 2,000 Debentures.
    • Price: $1,000 per Debenture.
    • Gross Proceeds: $2,000,000.
    • Interest: 10.0% per annum, payable semi-annually in arrears.
    • Maturity: December 31, 2029.
    • Conversion: Convertible into Common Shares at a price of $0.45 per share.
    • Seller Subscription: Juno Pharmaceuticals LP subscribed for $1,500,000 of the debentures.
  • Total Capital Raised:
    • Previous Brokered Offering: $10,000,000.
    • Current Non-Brokered Offering: $2,000,000.
    • Aggregate Gross Proceeds: $12,000,000.
  • Target Business Profile: Juno OTC is a supplier in the Canadian private label consumer healthcare OTC market, holding required Health Canada licenses for importing and distribution.

Notable Quotes

  • No direct quotes from the CEO/President were included in the provided text.
Read the original news release →

More from LSL Pharma Group Inc.